Clinical Trials Browser

Phase 2/3 × sargramostim × 90 days × Clear all

NCT02339571 2026-03-19

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Phase 2/3 Active not recruiting

Melanoma